Biotech is fraught with failure. A CEO's most important function is to embody an 'irrational belief' they will succeed against all odds. This conviction is a strategic tool for recruiting great people and motivating the team to overcome countless hurdles by focusing on the single reason it will work.

Apogee faced skepticism because their drug optimized a known target, which some investors deemed "too obvious" to be innovative. However, this focus on a clear patient need (less frequent injections) was precisely what made it valuable to patients, physicians, and ultimately, the acquirer AbbVie.

Upon joining Zevra as CEO, Neil McFarlane's first priority was creating focus. He identified filing the New Drug Application (NDA) for their lead rare disease asset as the single greatest value creator and stopped all other distracting activities to channel the organization's resources toward that one goal.

Sana CEO Steve Harr actively questions whether the company's groundbreaking science can translate into a scalable, commercially viable therapy. This internal pressure focuses the team on solving not just the scientific challenges ("does it work?"), but also manufacturing ("can you scale it?") and the commercial model required for a true cure.

Phillip Sharp explains that the decision to co-found Alnylam was driven by the enormous potential of RNAi to treat countless diseases. This massive upside of changing medicine dwarfed the downside risk of the company failing, making it a compelling venture despite the odds.

Novartis advanced Gleevec, a CML drug, despite a low $200M peak sales forecast because of its "outsized efficacy." This focus on patient impact over financial models led to a $7B blockbuster, proving that transformative clinical results can create their own market and override initial commercial doubts.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

Early in his career, Andy Robbins dismissed the potential of Revlimid, a drug that became a blockbuster. This mistake taught him to focus first on finding great science that solves a problem and then building a commercial strategy, rather than trying to fit science into a predefined large market.

While acknowledging that repurposing a failed drug feels like a "leap of faith," Declan Doogan stresses it's not a blind gamble. The successful pivot at Amarin was based on a "thorough and rigorous assessment of the science evidence based thinking," highlighting that radical strategic shifts must be built on a strong scientific foundation.